Premium
An abnormal digital rectal examination is an independent predictor of Gleason ≥7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men
Author(s) -
Borden Lester S.,
Wright Jonathan L.,
Kim Jason,
Latchamsetty Kalyan,
Porter Christopher R.
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06647.x
Subject(s) - medicine , rectal examination , prostate cancer , prostate , odds ratio , cancer , biopsy , prospective cohort study , prostate biopsy , confidence interval , multivariate analysis , population , gynecology , prostate specific antigen , urology , oncology , environmental health
OBJECTIVE To evaluate our experience with a referral population of 790 patients undergoing initial prostate biopsy in the prostate‐specific antigen (PSA) era, to assess the role of a digital rectal examination (DRE) in predicting the outcome of prostate needle biopsy (PNB) and to evaluate if DRE findings were associated with cancer grade. PATIENTS AND METHODS We analysed 790 consecutive men who had an initial PNB from September 1999 to July 2005 by one urologist (C.P.). All data were collected in a prospective database. Multivariate logistic regression analysis was used to determine the relationship between an abnormal DRE and the presence of cancer and cancer grade on PNB. RESULTS An abnormal DRE was an independent predictor for prostate cancer on multivariate analysis (odds ratio 2.18, 95% confidence interval 1.53–3.10, P < 0.001). In all patients biopsied, an abnormal DRE was associated with a Gleason sum of ≥ 7 on multivariate analysis (odds ratio 3.39, 2.07–5.53, P = 0.001). CONCLUSION A DRE is a useful and important tool to use when assessing patients for a PNB. An abnormal DRE independently predicted high‐grade disease in these men. These results might have important implications in the prediction of men with other than indolent prostate cancer.